

Substitute for Form 1449A/PTO & 1449B/PTO				Complete if Known
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number 10/506,543 Filing Date September 3, 2004 First Named Inventor KJELL OLMARKER Examiner Name Unassigned Robert Mondesi Attorney Docket Number 003301-175
Sheet	1	of	1	

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
RM	5,196,430		MANDRELL <i>et al.</i>	March 23, 1993
RM	5,994,376		FREYNE <i>et al.</i>	November 30, 1999
RM	6,348,602		FOWLER <i>et al.</i>	February 19, 2002

FOREIGN PATENT DOCUMENTS

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RM	STN International, File ZCPLUS, Accession No. 2002:199887, Document No. 136:323691, KASER, ARTHUR <i>et al.</i> , "Infliximab in Severe Steroid-Refractory Ulcerative Colitis: A Pilot Study", & Wiener Klinische Wochenschrift (2001), 113(23-24), 930-933.
	STN International, File MEDLINE, Accession No. 2000046083, Document No. 20046083, HELLER T. <i>et al.</i> , "Treatment of Severe Esophageal Crohn's Disease With Infliximab", & INFLAMMATORY BOWEL DISEASES, (1999 Nov.) 5 (4) 279-82.
	STN International, File MEDLINE, Accession No. 2001011857, Document No. 20409486, JOJIC N., "[Pharmacotherapy of Inflammatory Bowel Disease]. "Farmakoterapija Inflamatornih Bolesti Creva", & ACTA CHIRURGICA JUGOSLAVICA, (2000) 47 (1-2) 51-5.
	STN International, FILE MEDLINE, Accession No. 2001419273, Document No. 21360250, BLAM M.E., "Integrating Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Current and Future Perspectives", AMERICAN JOURNAL OF GASTROENTEROLOGY, (2001 Jul.) 96 (7) 1977-97.
↓	STN International, File MEDLINE, Accession No. 2001553668, Document No. 21486185, TRAVIS S.P. <i>et al.</i> , "Treatment of Intestinal Behcet's Syndrome With Chimeric Tumour Necrosis Factor Alpha Antibody", & GUT, (2001 Nov.) 49 (5) 725-8.

Examiner Signature	/Robert Mondesi/	Date Considered	01/09/2007
-----------------------	------------------	--------------------	------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application	10/506,543
Filing Date	October 13, 2004
First Named Inventor	Kjell OLMARKER
Examiner Name	Robert B. Mondesi
Attorney Docket No.	1003301-000175

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS					
					Translation	Partial Translation	Search Report	Eng Lang. Summary	Abstract	Cited in Spec

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
RM	Black L.E. "Pharmacology review of infliximab BLA" - 21-05-1998-found at internet address:
	http://www.fda.gov/cder/biologics/review/inflicen082498r4.pdf

Examiner Signature	/Robert Mondesi/	Date Considered	01/09/2007
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.